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Aims: Do biobanks enact policies and plans that allow them to anticipate and respond to potential challenges? If
a biobank has one such policy or plan, is it likely to have more? Using survey data from 456 U.S. biobanks, we
assess four possible indicators of such ‘‘forward-thinking.’’
Methods: We present response frequencies and cross-tabulations regarding policies for return of results and
ownership of specimens, and for having a formal business plan and a plan for what happens to specimens if the
biobank closes. We analyze the relationships among these indicators, using chi-square for tests of statistical
significance.
Results: Policies—Sixty-two percent of biobanks have a policy about returning individual research results; 70%
have a policy designating ownership of specimens and/or technology. Having these two policies is significantly
related ( p< 0.001). Plans—34% of biobanks have a formal business plan; 26% have a written plan for what will
happen to the specimens if the biobank closes. Having these two plans is significantly related (p< 0.001).
Relationships among indicators—only 7% of biobanks are forward-thinking across all four indicators; 12% are
forward-thinking across none.
Discussion: The two policies we examined tend to occur together, as do the two plans. These policies and plans
seem to tap different aspects of accountability and responsiveness. Specifically, the policies reflect issues most
commonly raised in the ethical and legal literature on biobanking, while the plans are indicators of sustain-
ability, a separate area of concern in biobanking.
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Introduction
B iobanks are extremely heterogeneous institutions(Gibbons, 2009; Henderson et al., 2013a). They vary in
multiple ways, including size, purpose, types of specimens
collected, affiliations with larger organizations, and sources
of funding (Henderson et al., 2013a). While biobanks have
been in existence for decades, only recently has there been a
‘‘boom’’ in the industry (Tupasela and Stephens, 2013),
generating increased interest in the ethical, legal, and social
issues (ELSI) associated with biobanks, as well as their long-
term sustainability. The ELSI literature on biobanking has
focused on issues such as informed consent, data sharing,
privacy, identifiability, public trust, and approaches to gov-
ernance (e.g., Haga and Beskow, 2008; Hansson, 2009).
The biobanking industry has been described as ‘‘highly dy-
namic’’ (O’Doherty et al., 2011) and ‘‘precarious’’ (Stephens
and Dimond, 2015a). This, coupled with the tremendous growth
of the industry, has necessitated that responsible biobanks reflect
upon and address the implications of relevant challenges, in-
cluding potential identifiability of specimen donors, government
requirements for data sharing, and other developments in tech-
nology, regulation, and funding. The literature on biobanking
has suggested that biobanks continuously evaluate how they
are meeting their goals, anticipating and planning for challenges
rather than simply responding to problems when they arise
(Laurie et al., 2011; O’Doherty et al., 2011).
The need for biobank policies and plans to facilitate such
analysis and foresight is frequently addressed in the ELSI
literature (e.g., O’Doherty et al., 2011; Laurie et al., 2012;
Stephens and Dimond, 2015b) and the literature on sustain-
ability (e.g., Albert et al., 2014; Simeon-Dubach and Hen-
derson, 2014). In this article, we use data from our U.S.
Biobank Survey to examine whether biobanks have policies
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and plans that allow them to anticipate and be responsive to
potential challenges. Specifically, we look at ways biobanks
deliberately address potential challenges, and we call these
indicators of ‘‘forward-thinking’’ biobanks.
We use the following as indicators of forward-thinking
biobanks: having a policy on ownership of specimens or
rights to technologies developed from research uses of the
specimens, having a policy on return of individual results
derived from use of specimens, having a formal business
plan, and having a plan for termination. Each feature is dis-
cussed in the Background section.
Background
Elsewhere, we have reported on biobank practices, de-
tailing how biobanks steward specimens from collection
through storage and use by researchers (Henderson et al.,
2013b). In this article, we turn to biobank policies and formal
plans, arguing that they represent ways that biobanks antic-
ipate and address potential future challenges, or exhibit
forward-thinking. Furthermore, we explore whether forward-
thinking in one such policy or plan is associated with
forward-thinking in others.
Policies on return of individual research results and on
designation of ownership rights have long been foci of debate
among ELSI scholars (e.g., Dressler, 2007; Rao, 2007; de
Faria, 2009; Wolf et al., 2012; Jarvik et al., 2014). Biobank
best practice guidelines acknowledge the need for biobanks
to address them, yet no specific strategies are described (NCI,
2011; ISBER, 2012). In contrast, creating a business plan and
a plan for termination are both strongly recommended within
practice guidelines (OECD, 2009; NCI, 2011; ISBER, 2012)
and are familiar generally in the world of business, but are
largely ignored by ELSI scholars (Cadigan et al., 2013).
Return of individual results policy. With few exceptions
( Johnson et al., 2012), little is known about biobanks’ poli-
cies regarding returning individual research results [else-
where we describe biobanks’ reported practices regarding the
return of research results (Henderson et al., 2013b)]. The
question of whether or not biobanks have a responsibility to
return individual research results to participants is deliber-
ated by those interested in the ethical and legal concerns
regarding biobanking (Wolf et al., 2012). The International
Society for Biological and Environmental Repositories
(ISBER) acknowledges that return of results is a complex and
important ethical issue that should be discussed with an ethics
review board before repositories are established (ISBER,
2012). Similarly, National Cancer Institute (NCI) guidelines
state that biobank governance plans should outline protocols
for handling research results (NCI, 2011).
Dressler (2009:94) notes that while international guide-
lines related to biobanking often support an ethical duty to
disclose research results, ‘‘There are no consistent criteria to
aid a biobanker or researcher in determining when and if a
research result may be of benefit to an individual participant.
Therefore, the practical interpretation and application of
these guidelines, on a daily basis, is still a challenge.’’ Other
researchers have argued that if a biobank fails to address the
issue of return of individual results, it could undermine its
relationship with existing and future specimen contributors,
and the resulting ‘‘lack of trust could lead to operational
unsustainability’’ (Simeon-Dubach and Henderson, 2014:288).
Consequently, we regard having a policy on return of indi-
vidual results as an indicator of a biobank’s consideration
of this contentious issue; so for our analyses, a biobank is
forward-thinking if it has such a policy.
Policy on designation of ownership rights. Collecting and
storing specimens for long periods of time for future research
raises questions about ownership. To date, there is little federal
law addressing ownership of specimens in biobanks or rights
to technologies developed from research use of the specimens.
Given that uncertainty, best practice guidelines largely side-
step ownership of specimens or technology altogether, or-
ienting their guidance toward authority to control the use and
storage of specimens, such as references to biobanks as
‘‘custodians’’ of specimens (NCI, 2011; ISBER, 2012). Thus,
neither policy nor practice regarding ownership of specimens
and/or related technologies is well-developed. Common law
has offered some guidance, although incomplete.
Rights to the physical property of human specimens have
been litigated in the United States (Moore v. Regents of the
University of California, Washington University v. Catalona,
Greenberg v. Miami Children’s Hospital) and more recently
before an Ontario, Canada, superior court (Piljak Estate v.
Abraham, 2014). Some cases, like Moore and Greenberg,
address relevant related technologies as well (Lepsch, 2012;
Ormond and Cho, 2014). However, the numerous ownership
disputes that are not litigated remind us that courts of law do
not remedy all ownership issues (e.g., De Souza and Green-
span, 2013; Ormond and Cho, 2014). Furthermore, high profile
cases brought to public attention through the publication of a
book detailing the story of Henrietta Lacks and the HeLA cell
line (Skloot, 2010) or by the media’s portrayal of the plight of
the Havasupai Native Americans in a legal battle over the
extent of research uses of their specimens (Havasupai Tribe v.
Arizona Board of Regents; Mello and Wolf, 2010), highlight
how contentious perceptions of ownership can become.
Consequently, we view having a policy about ownership of
specimens and/or rights to technologies developed from the
use of specimens to be evidence of a forward-thinking bio-
bank because it displays consideration of the complexities of
the rights associated with ownership and anticipates chal-
lenges that could ensue from it.
Formal business plan. Best practice guidelines for bio-
banks recommend that biobanks create a business plan to
formalize their operations and account for their operational
costs (NCI, 2011; Vaught et al., 2011b; ISBER, 2012). Other
guidelines recommend that a biobank should be ‘‘explicit
and transparent about the nature and source of its financing/
funding’’ (OECD, 2009:4). These recommendations hinge on
the need for long-term funding to build and sustain a biobank.
Others have argued that a biobank must communicate its
commitment to fundamental business practices and its un-
derstanding of the costs of conducting business to persuade
potential funders (Vaught et al., 2011a).
Funding for biobanking is notoriously insecure (Vaught
et al., 2011a). Elsewhere, we have reported results from our
U.S. Biobank Survey, which indicate that most biobanks are
funded from multiple sources and dependent on government
funding, and that support is often in the form of short-term
grants (Cadigan et al., 2013; Henderson et al., 2013a). Over
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70% of our survey respondents said that they had major or
moderate concerns about their biobank running out of funding
(Henderson et al., 2013a).
While having a business plan does not necessarily indicate
increased financial security for a biobank, accounting for
business costs, customer needs, and areas of growth required
when creating a business plan can lead to future stability
(Simeon-Dubach and Henderson, 2014). In addition, a busi-
ness plan is an expression of accountability to others inter-
ested in the legitimacy of the biobank. These parties include
not only potential funders but also the researchers who serve
as their customers and the individuals who contribute spec-
imens. Consequently, we view having a business plan as an
indication of forward-thinking.
Plan for termination. Biobanks may be terminated, often
due to lack of funding (Zawati et al., 2011; Cadigan et al.,
2013; Tupasela and Stephens, 2013; Stephens and Dimond,
2015a, 2015b). Best practice guidelines for biobanks rec-
ommend creating plans for termination and that any transfer
of specimens or data to third parties upon termination should
be consistent with the informed consent under which speci-
mens or data were obtained (OECD, 2009; NCI, 2011;
ISBER, 2012). Plans for termination, also called legacy
plans, can address the uncertainty arising from the potential
mismatch between the original purpose of collection and
subsequent use of specimens (Matzke et al., 2016).
Some have argued that termination plans that promote the
use of the biobank’s resources in accordance with its original
purposes can promote public trust (Laurie, 2011). Recent data
reveal that potential specimen contributors think it is very
important to be informed, before joining the biobank, of the
contingency plan for specimens and data in the event of clo-
sure (Long et al., 2015). Ensuring that future use of specimens
is in line with what contributors expect is an important issue to
consider if biobanks’ collections are to be transferred to new
owners and/or combined with other collections.
In other businesses, plans for termination (or other con-
tingency plans), may be set forth in statutory requirements,
such as provisions for corporate dissolution. Such plans for
corporations contemplate disposition of assets and property,
accounting for liabilities and proper notice provisions to
parties who may have outstanding claims (see e.g., NCGS 55-
14-01 et seq). These existing models, and an appreciation that
biobanks have failed in the past (by disappearing, bank-
ruptcy, or acquisition), are convincing reasons for forward-
thinking biobanks to create plans for termination.
Methods
Detailed information about our 2012 national survey of
biobanks, including our recruitment methods, is provided
elsewhere (Henderson et al., 2013a). We employed a multi-
faceted search strategy to create a list of U.S. biobanks, which
we defined as ‘‘organizations that acquire and store human
specimens and associated data for future research use’’
(Boyer et al., 2012). For each biobank on our list, we re-
cruited the director (or other knowledgeable representative)
to complete the survey. We asked that the representative be
thoroughly knowledgeable about the policies and practices of
the biobank and encouraged the representative to confer with
others in the biobank, if necessary, to answer the survey
questions accurately. We also instructed representatives that
if they could not find the answer to a survey question, to
please skip it (see Cadigan et al., 2013 for more information).
Representatives were sent an invitation letter, followed by
an email with a link to the 30-min online survey, which was
preceded by an informed consent statement. Of 636 eligible
biobanks, representatives of 456 (72%) completed the sur-
vey. For the analyses presented in this study, we exclude 27
biobanks that store specimens for researchers who collected
and deposited them, but do not share with other researchers.
The University of North Carolina IRB approved this study.
Survey data were collected using Illume software version 4.7
(Datstat, Inc., Seattle, WA).
Data were analyzed in SAS version 9.2 (SAS Institute,
Inc., Cary, NC). We present response frequencies and cross-
tabulations, with percentages where appropriate. Where
percentages do not add to 100, it is due to rounding. In ex-
amining bivariate relationships, we use chi-square to test the
null hypothesis that the variables are independent.
Results
Below, we report results for each of our forward-thinking
indicators and then discuss relationships among them.
Return of individual results
To be eligible to answer our questions about return of results,
we first asked respondents whether their biobank has access
to identifying information for any of their specimen contribu-
tors because we reasoned that without access to identifying
information, a biobank could not return results. Three hundred
twenty-seven (77% of the total sample) indicated they had
access to identifying information. We asked these survey re-
spondents whether their biobank has a policy about returning
individual results to specimen contributors (or to their surro-
gates, in the case of pediatric or postmortem specimens). Sixty-
two percent of these 327 survey respondents said that the
biobank does have a policy, 28% reported that it does not, and
10% said they were not sure. For the 62% with a policy, we
asked what the policy specifies—whether results will be re-
turned always, under certain conditions, or never. For the ma-
jority, 57%, the policy states that results will never be returned,
for 38% results will be returned under certain conditions, and
results will always be returned for only 5%.
For those biobanks that do have a policy on return of indi-
vidual results, we also asked whether the policy addresses the
issue of incidental findings, which we defined as ‘‘findings
beyond the initial aims of the research.’’ Fifty-two percent of
respondents indicated that the policy also addresses this issue.
These respondents were then asked whether the incidental
findings policy states that they will be returned always, under
certain conditions, or never. Just over half (51%) responded
that incidental findings are returned under certain conditions,
while 42% responded that they are never returned, and 7%
indicated that they are always returned. For this article, a bio-
bank is forward-thinking if they have a return of results policy,
regardless of whether the policy includes incidental findings.
Policy on designation of ownership rights
We asked survey respondents, ‘‘Does [biobank] have a
policy that designates who owns its specimens?’’ Sixty-one
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percent responded ‘‘yes,’’ 16% said ‘‘no,’’ and 22% said they
were ‘‘not sure.’’ We also asked respondents whether the
biobank has a policy that designates who owns the rights to
technologies developed from research done with the speci-
mens. Forty-four percent of respondents said their biobank has
a policy designating ownership of these rights, 19% said the
biobank does not, and 15% said they were not sure. An addi-
tional 21% indicated that the question was ‘‘not applicable’’
because no technologies are developed. Fewer respondents
indicated their biobank has a policy about ownership rights to
technologies developed from research with the specimens than
ownership of the specimens themselves. One hundred seventy-
three respondents said the biobank has a specimen ownership
policy and also answered the question regarding ownership
rights to technologies with a ‘‘yes’’ or ‘‘no’’ (i.e., they did not
respond ‘‘not sure or ‘‘not applicable’’). Of these 173 respon-
dents, 132 (76%) indicated that the biobank does have a policy
regarding ownership of rights to technologies. Only 14 re-
spondents indicated that their biobank has a policy regarding
ownership of rights to technologies, but not a policy on own-
ership of specimens. For this article, we label a biobank as
forward-thinking if it has either a policy on ownership of
specimens or on ownership of technologies developed from
research use of the specimens.
Formal business plan
In our survey, we asked all respondents, ‘‘Does [biobank]
have a formal business plan?’’ Thirty-four percent reported
that they do, while 66% said they do not.
Plan for termination
We asked survey respondents, ‘‘Does [biobank] have a
written plan for what will happen to the specimens should the
biobank be terminated for any reason?’’ Twenty-six percent
reported that the biobank does have a plan for termination,
51% reported that it does not, and 24% said they were not
sure whether the biobank has a termination plan.
Bivariate relationships among the forward-thinking
variables
We investigated whether and how these four variables are
related because we hypothesized that if a biobank was forward-
thinking in one area, it was more likely to be forward-thinking
in others. Thus, we examined cross-tabulations between each
pair of variables. Three relationships are statistically significant
(depicted in Tables 1–3): having a policy about ownership of
specimens and/or technology is associated with having a policy
about return of individual results (w2 13.30, p< 0.001; Table 1).
Having a policy about ownership of specimens and/or tech-
nology is associated with having a plan for termination (w2
14.08, p< 0.001; Table 2). Having a plan for termination is
associated with having a formal business plan (w2 17.11,
p< 0.001; Table 3). Because we have no causal hypotheses
about the relationships, we include row and column percent-
ages in Tables 1–3.
Patterns of forward-thinking variables
To further explore relationships between the indicators of
forward-thinking biobanks, we examined our four variables in
combination. In this way, we could examine the proportion of
biobanks that may be forward-thinking in only one or two
ways and those that are forward-thinking along all four vari-
ables.1 Biobanks were excluded from these analyses if they
were not asked or chose not to answer any of the related
survey questions. A total of 312 biobanks are included in this
analysis. We analyzed all possible combinations of the four
forward-thinking indicators. The results are shown in Table 4.
We observed patterns among the 312 biobanks that an-
swered questions about all four forward-thinking variables.
One-fifth of these biobanks (n = 62) have policies on return of
results and ownership, but no business plan or plan for
Table 1. Ownership and Return of Results
Policy about
ownership of specimens
and/or technologies
Policy about return
of individual resultsa
TotalYes No
Yes—n 157 56 213
Row % 73 27 100
Column % 89 70 84
No—n 19 23 42
Row % 45 55 100
Column % 11 30 16
Total—n 176 79 255
Row % 69 31 100
Column % 100 100 100
w2 = 13.30, p < 0.001.
Seventy-eight additional respondents answered one or both of the
questions with ‘‘Not Sure’’ or left it blank and are therefore omitted
from this table.
aNinety-six respondents were not asked this question because
their biobank does not have identifying information for any of its
specimens and therefore could never return results.
Table 2. Ownership and Plan for Termination
Policy about ownership
of specimens and/or
technologies
Plan for termination
TotalYes No
Yes—n 97 143 240
Row % 40 60 100
Column % 94 77 83
No—n 6 43 49
Row % 12 88 100
Column % 6 23 17
Total—n 103 186 289
Row % 36 64 100
Column % 100 100 100
w2= 14.08, p < 0.001.
One hundred forty respondents answered one or both questions
with ‘‘Not Sure’’ or left one/both blank and are therefore omitted
from this table.
1In this analysis, we first used only the ‘‘yes’’ and ‘‘no’’ re-
sponses, omitting the ‘‘not sure’’ answers for the three variables that
included this response option (policies on ownership and return of
individual research results and a plan for termination). When we
found that combining ‘‘not sure’’ with ‘‘no’’ responses did not
change the results, we included those ‘‘not sure’’ responses with the
‘‘no’’ responses.
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termination (row 4). Fourteen percent (n = 45) have a return
of results policy, but are not forward-thinking in any other
variables (row 2). Twelve percent (n = 38) are not forward-
thinking for any variable (row 1). Eleven percent (n = 34)
have only ownership policies (row 3). Finally, only 7% of
these biobanks (N = 23) are forward-thinking across all four
variables (row 16).
Discussion
Biobanking is an evolving field. What began as small
collections, often based at academic medical centers and
focused on fulfilling the needs of specific studies, have grown
into an emerging industry (De Souza and Greenspan, 2013;
Henderson et al., 2013a). This is evident in publications of
guidelines for best practices in biobanking (OECD, 2009;
NCI, 2011; ISBER, 2012) as well as the development of an
extensive accreditation program for biobanks (College of
American Pathologists). These efforts may help to improve
the quality and consistency of biobank collections. They may
also help to increase public trust and confidence from research
users and funders by, among other things, providing evidence
of professionalism, adaptability, and foresight (O’Doherty et al.,
2011; Laurie et al., 2012; Simeon-Dubach and Henderson,
2014). Commentators suggest that biobanks have been guided
mainly by the ‘‘quest for research’’ rather than by the standard
conventions of business practice, where examination of supply
and demand, and the application of basic business principles
would guide the creation and maintenance of a successful
business (Vaught et al., 2011a).
We argue that forward-thinking policies and plans are other
indicators of anticipatory planning. In this article, we use four
variables from our survey of U.S. biobanks. The variables we
highlight as indicators of forward-thinking biobanks are just
some that could be examined. For example, elsewhere, we
report on biobanks’ ‘‘reach through’’ practices after distrib-
uting specimens or data to researchers (Henderson et al.,
2013b). We defined ‘‘reach through’’ as the extent to which
biobanks retain or relinquish control of the specimens or data
after sharing them. We could have argued here, for instance,
that forward-thinking biobanks are those that require re-
searchers to return aggregate results to the biobank from the
studies using its specimens (Henderson et al., 2013a). Alter-
natively, we could have examined the presence or absence of
oversight committees (Henderson et al., 2013a).
However, for this article, we chose our variables of interest
because they reflect two different kinds of anticipatory plan-
ning that are frequently discussed in the literature on bio-
banking, but usually not together: ethical and legal issues and
sustainability of the biobank. Policies on return of individual
research results and incidental findings, as well as policies on
ownership of specimens and technologies, reflect planning
related to contentious ethical and legal issues. Debate over the
ethical issues raised by return of research results is commonly
found in the bioethics literature, while ownership issues have
Table 3. Formal Business Plan
and Plan for Termination
Formal business
plan
Plan for termination
TotalYes No
Yes—n 52 56 108
Row % 48 52 100
Column % 50 27 35
No—n 51 153 204
Row % 25 75 100
Column % 50 73 65
Total—n 103 209 312
Row % 33 67 100
Column % 100 100 100
w2 = 17.11, p < 0.001.
One hundred seventeen respondents answered one or both
questions with ‘‘Not Sure’’ or left one/both blank and are therefore
omitted from this table.
Table 4. Patterns of Forward-Thinking Variables
Row no.
Formal
business plan
Plan for
termination
Ownership
policya
Return of
results policy Frequency Percentage
1 N N N N 38 12
2 N N N Y 45 14
3 N N Y N 34 11
4 N N Y Y 62 20
5 N Y N N 3 1
6 N Y N Y 3 1
7 N Y Y N 5 2
8 N Y Y Y 28 9
9 Y N N N 13 4
10 Y N N Y 10 3
11 Y N Y N 18 6
12 Y N Y Y 22 7
13 Y Y N N 2 1
14 Y Y N Y 2 1
15 Y Y Y N 4 1
16 Y Y Y Y 23 7
Total 312 100
aY if policy on ownership of specimens and/or technology.
Y, Has policy/plan; N, Does not have policy/plan.
152 CADIGAN ET AL.
been debated in courts and in the media. Having a business
plan and a plan for termination of the biobank reflect formal
planning related to sustainability, which we have argued
elsewhere is also an ethical issue (Cadigan et al., 2013).
In our survey, 62% of biobanks that have access to identi-
fying information report they have a return of individual results
policy. Interestingly, although international guidance on bio-
banking leans toward returning individual results to contribu-
tors, for the majority of biobanks in our study with a policy
(57%), the policy states that results will never be returned.
Seventy percent of the biobanks in our survey report having a
policy on ownership of specimens and/or technology. Biobanks
were far less likely to have plans related to sustainability (34%
have a business plan and 26% have a termination plan). When
we examined patterns among biobanks that provided answers
to all four variables, we discovered that only 7% were forward-
thinking across all four variables, and 12% were not forward-
thinking for any of the variables.
Having a return of results policy and an ownership policy
were significantly related, as were having a business plan and
termination plan. Interestingly, we also found a significant
relationship between biobanks having an ownership policy
and a plan for termination. This may indicate that biobanks
that find it important to formally designate ownership are also
more mindful of the need to develop legacy plans for the
specimens and data should the biobank close. In fact, one best
practice guideline recommends, regarding ‘‘business risks,’’
that biobanks ‘‘provide [specimen contributors] information
that ownership could change and explain the uncertainties
associated with the establishment and operation of the [bio-
bank]’’ (OECD, 2009:24).
Our study of biobanks has limitations. It is not a longitu-
dinal study, so we cannot examine whether biobanks’ poli-
cies have changed over time, which might further indicate
their ability to be adaptive (O’Doherty et al., 2011). In ad-
dition, our survey did not ask respondents about the return of
individual results if they reported that their biobank does not
have access to identifying information for any of its specimen
contributors. We could have labeled these biobanks as not
forward-thinking for our analyses in this study, arguing that
biobanks with specimens and data that are linked to indi-
viduals are forward-thinking by anticipating that the value
of the collection is increased with such linkages. However,
we chose not to do so because we lack data on why these
biobanks do not have access to identifying information. It
is possible, for instance, that an honest broker has access,
but the biobank itself does not (Boyd et al., 2007). Therefore,
we did not feel comfortable labeling them as not forward-
thinking. Further research should be done to understand the
different circumstances under which biobanks do not retain
identifying information.
We argue that given the uncertainties of biobanking, it is
critical to develop policies and plans such as those we ex-
amine in this report. Furthermore, in the new era of ‘‘preci-
sion medicine,’’ which hopes to capitalize on specimens and
data already collected and stored for large-scale research
projects (Collins and Varmus, 2015), it is increasingly im-
portant that biobanks evidence professionalism and ac-
countability. For any organization to be sustainable, certain
levels of planning must be met. Forward-thinking in bio-
banking means anticipating future challenges and creating
both policies and procedures to address them.
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